Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
- Authors: Kolyadina IV1,2, Poddubnaya IV1,2, Van de Velde C.J.3, Kuppen PJ.3, Frank GA1, Komov DV2, Karseladze AI2, Bastiaannet E3, Dekker-Ensink NG3
-
Affiliations:
- Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation
- N.N.Blokhin Russian Cancer Research Center
- Leiden University Medical Center (LUMC). Leiden, The Netherlands, Department of Surgery
- Issue: Vol 17, No 1 (2015)
- Pages: 30-38
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26991
- ID: 26991
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I V Kolyadina
Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation; N.N.Blokhin Russian Cancer Research Center
Email: irinakolyadina@yandex.ru
канд. мед. наук, доц. каф. онкологии ГБОУ ДПО РМАПО, ФГБНУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
I V Poddubnaya
Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation; N.N.Blokhin Russian Cancer Research Centerчл.-кор. РАН, д-р мед. наук, проф., зав. каф. онкологии ГБОУ ДПО РМАПО, ФГБНУ РОНЦ им. Н.Н.Блохина 125993 Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
Cornelis JH Van de Velde
Leiden University Medical Center (LUMC). Leiden, The Netherlands, Department of Surgeryпроф., глава отд. хирургической онкологии LUMC K6-R P.O. Box 9600, 2300 RC
P JK Kuppen
Leiden University Medical Center (LUMC). Leiden, The Netherlands, Department of SurgeryPhD, глава исследовательской лаб. LUMC K6-R P.O. Box 9600, 2300 RC
G A Frank
Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. каф. патологической анатомии ГБОУ ДПО РМАПО 125993 Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
D V Komov
N.N.Blokhin Russian Cancer Research Centerд-р мед. наук, проф., зав. отд-нием хирургической диагностики опухолей ФГБНУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A I Karseladze
N.N.Blokhin Russian Cancer Research Centerд-р мед. наук, проф., зав. отд-нием патологической анатомии опухолей ФГБНУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E Bastiaannet
Leiden University Medical Center (LUMC). Leiden, The Netherlands, Department of SurgeryPhD, сотр. отд. медицинской статистики LUMC K6-R P.O. Box 9600, 2300 RC
N G Dekker-Ensink
Leiden University Medical Center (LUMC). Leiden, The Netherlands, Department of SurgeryPhD, сотр. исследовательской лаб. LUMC K6-R P.O. Box 9600, 2300 RC
References
- Nicolini A, Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 2009; 29: 436-71.
- De Kruijf E.M, Sajet A, van Nes J.G et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010; 185: 7452-9.
- Engels C.C, Charehbili A, Van de Velde C.J et al. The prognostic and predictive value of Tregs and tumor immune subtypes in post - menopausal, hormone receptor - positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat 2015; 149 (3): 587-96.
- Garc-Тa-Mart-Тnez E, Luengo Gil G, Chaves Benito A Tumor - infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res 2014; 16 (6): 488.
- Finn O.J. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
- Kaneko K, Ishigami S, Kijima Y. Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011; 11: 454.
- Cabrera T, Angustias Fernandez M, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996; 50: 127-34.
- Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000; 343: 702-9.
- Powell A.G, Horgan P.G, Edwards J. The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key? J Cancer Res Clin Oncol 2012; 138: 723-8.
- Shenouda G, Thomson DM. Blocking of the response by human T-lymphocytes to extracts of autologous cancer by monoclonal antibody to Class-I major histocompatibility complex gene products in the leukocyte adherence inhibition assay. Cancer Res 1984; 44 (7): 2762-8.
- Curigliano G, Criscitiello C, Gelao L. Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 2013; 19 (20): 5564-71.
- Dong D.D, Yie S.M, Li K et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol 2012; 73: 998-1004.
- Ramos C.S, Gon Нalves A.S, Marinho L.C. Analysis of HLA-G gene polymorphism and protein expression in invasive breast ductal carcinoma. Hum Immunol 2014; 75 (7): 667-72.
- Da Silva G.B, Silva T.G, Duarte R.A. Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer. Int J Breast Cancer 2013; 2013: 250-435.
- Jeong S, Park S, Park B.W. Human leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patients. PLoS One 2014; 9 (5): e98284.
- Mao Y, Qu Q, Zhang Y. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy inbreast cancer: a systematic review and meta - analysis. PLoS One 2014; 9 (12): e115103.
- Chan M.S, Chen S.F, Felizola S.J Correlation of tumor - infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients. Int J Biol Markers 2014; 29 (3): e193-203.
- Kim S.T, Jeong H, Woo O.H. Tumor - infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 2013; 36 (3): 224-31.
- Miyashita M, Sasano H, Tamaki K. Tumor - infiltrating CD8+ and FOXP3+ lymphocytes in triple - negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2014; 148 (3): 525-34.
- Liu S, Foulkes W.D, Leung S. Prognostic significance of FOXP3+ tumor - infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014; 16 (5): 432.
- De Kruijf E.M, Engels C.C, Van de Water W. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat 2013; 142 (2): 355-64.